P10.19.A COMBINED TREATMENT USING MAPK AND PI3K SIGNALING PATHWAYS INHIBITORS EFFECTIVELY REDUCES GROWTH OF MELANOMA BRAIN METASTASIS CELLS IN VITRO

Abstract

Abstract BACKGROUND Brain metastasis is associated with poor prognosis, and median survival time from the time of diagnosis for cancer patients with brain metastases is only a few months. Brain metastases are estimated to occur in 20-40% of cancer patients. All solid tumors may spread to the brain, but the risk of developing brain metastases is higher in breast cancer, lung cancer and melanoma. Standard treatment of melanoma brain metastases (MBM) includes radiation therapy and surgery. In melanoma, the mitogen activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) signaling pathways are often activated by genetic alterations. An activation mutation (BRAFV600E) in the MAPK pathway is commonly found in melanoma refractory to therapy. This mutation leads to increased proliferation and tumor cell survival. Previous studies show that BRAF-inhibitors block the increase in cell proliferation induced by the activated BRAF gene, however, many of the patients develop drug resistance within a few months. Objectives: In this project, we aimed to show that drugs targeting BRAF (vemurafenib) and PI3K pathways (buparlisib) used in combination effectively inhibit growth of treatment resistant MBM cells. MATERIAL AND METHODS Our research lab has previously developed human MBM cell lines, which have been made resistant towards vemurafenib treatment. To study the potential antitumoral effects of combined treatment we used these cells in several in vitro assays such as cell viability and proliferation, cell migration, colony forming assay, spheroid growth, apoptosis by IncuCyte and western blot to confirm effects on signaling pathways. RESULTS We found that combination treatment reduced the viability of resistant MBM cells, as well as their ability to proliferate. Further, the cells showed less ability to migrate after therapy. Altered cell morphology was also seen. Initial results show effects on colony formation and increased apoptosis after combined treatment. CONCLUSION A combination of MAPK and PI3K inhibitors effectively inhibits growth and viability of treatment resistant human MBM cells, compared to single drug treatment alone. The results support clinical use of combined therapy for melanoma patients with metastatic disease.